BIO-Europe 2011 belicht nieuwe allianties en baanbrekende deals
Array
Niet-traditionele allianties in de gezondheidszorg en de opvallende baanbrekende deals van dit jaar zijn de onderwerpen van dieptediscussies op de opening en de plenaire sessies van BIO-Europe 2011, dat plaatsvindt van 31 oktober t/m 2 november in het CCD Congrescentrum in Düsseldorf.
Tijdens de plenaire openingsessie, die de niet-traditionele samenwerking in het nieuwe ecosysteem van de gezondheidszorg tot onderwerp heeft, discussieren panelleden, die resp. Bayer Pharma AG, QIAGEN en Roche vertegenwoordigen, onder leiding van moderator Patrick Flochel van Ernst & Young over de ontwikkeling van allianties door verschillende partijen om aan de vereisten van gepersonaliseerde medicatie tegemoet te komen.
Engelstalig bericht:
ZURICH & DUESSELDORF, Germany–(BUSINESS WIRE)– 20111006 —
Non-traditional healthcare alliances and the year’s prominent transformational deals will be the topics of in-depth discussion in the opening and keynote plenary sessions at BIO-Europe® 2011, being held October 31–November 2 at the CCD Congress Center in Duesseldorf, Germany.
In the opening plenary session, “Non-traditional Partnerships in the New Healthcare Ecosystem,†moderator Patrick Flochel of Ernst & Young will lead panelists Joerg Moeller, Bayer Pharma AG; Peer M. Schatz, QIAGEN; and Dan Zabrowski, Roche, in a compelling discussion about how diverse groups of players are developing alliances to meet the demands of personalized medicine.
“Partnerships with non-traditional players are becoming key for the development of important new treatment options,†said Carola Schropp, President of EBD Group. “BIO-Europe is an ideal venue for these players to present themselves and for traditional companies to scout for new partners.â€
The ninth annual “A Day in the Life of Experienced Dealmakers†will focus on “Transformational Deals that Shaped the Industry in 2011.†Moderator Anton Gueth, Burrill & Company will join panelists Mercedes Diz, Almirall; Gunnar GÃ¥rdemyr, Nycomed; James O’Mara, Ironwood Pharmaceuticals; Catherine A. Sazdanoff, Takeda Pharmaceuticals; and Jack Tupman, Eli Lilly, in a revealing debate about the transformational deals in 2011 that have changed the competitive landscape and their companies’ position in the industry.
“I look forward to this discussion at BIO-Europe around transformational deals. The Nycomed acquisition is truly a transformational deal for Takeda and Nycomed, as it opens important new strategic opportunities for us,†said Gunnar GÃ¥rdemyr, Senior VP of Corporate Development/M&A at Nycomed. “Together with my Takeda counterpart, I look forward to discussing how the deal came about, what this collaboration means for both parties and how it creates additional opportunities to build value as one company.â€
BIO-Europe is Europe’s largest partnering event serving the global biotechnology industry. BIO-Europe 2010 saw 14,661 one-to-one meetings conducted by 2,906 attendees from 1,688 companies. The event features partneringONE®, the industry’s most advanced web-based partnering system, enabling delegates from all parts of the biotechnology value chain to quickly identify, engage and enter into strategic relationships that drive their business successfully forward.
For more information or to register, visit www.ebdgroup.com/bioeurope
